BGM Group Ltd. regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Form 20-F annual report for the fiscal year ended September 30, 2025, on July 21, 2026. The Nasdaq Staff confirmed compliance on July 24, 2026, resolving the deficiency that arose from the delayed filing. The company operates in the biotechnology and pharmaceutical industry.
